Table 4.

Observed Estimates of 13-Valent Pneumococcal Conjugate Vaccine Effectiveness

	IRR (95% CI)	Change in disease rate, % (95% CI)
All IPD
Post-PCV (2016–2018)	0.621 (.364–1.029)	−37.9 (−63.6 to 2.9)
Early (2016–2017)	0.649 (.354–1.131)	−35.1 (−64.6 to 13.1)
Late (2018)	0.556 (.212–1.211)	−44.4 (−78.8 to 21.1)
VT IPD
Post-PCV (2016–2018)	0.577 (.327–.985)	−42.3 (−67.3 to 1.5)
Early (2016–2017)	0.655 (.350–1.163)	−34.5 (−64.9 to 16.3)
Late (2018)	0.399 (.120–.992)	−60.1 (−88.0 to .8)
NVT IPD
Post-PCV (2016–2018)	1.185 (.219–6.404)	18.5 (−78.1 to 540.4)
Early (2016–2017)	0.568 (.028–4.435)	−43.2 (−97.2 to 343.5)
Late (2018)	2.596 (.342–15.666)	159.6 (−65.8 to 1466.6)

Based on pre- and post-PCV IPD data in hospitalized children aged <5 years, 1 January 2012 to 31 December 2018.

Abbreviations: CI, confidence interval; IPD, invasive pneumococcal disease; IRR, incidence rate ratio; NVT, nonvaccine type; VT, vaccine type.